logo
logo

Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases

Mar 02, 2020•over 5 years ago

Amount Raised

$7 Million

Round Type

seed

San Diego

Description

 Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate immunity. Investors in the seed financing were CAM Capital, Charlie McDermott, BioBrit, and BioRock Ventures.

Company Information

Company

Primmune Therapeutics

Location

San Diego, California, United States

About

Primmune Therapeutics is harnessing the power of the innate immune system to develop small molecule, orally administered toll-like receptor 7 (TLR7) agonists as immunotherapies for the treatment of cancer and viral diseases. For more information, please visit: www.primmunerx.com.